Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Search Seller Projects – Europe,
Europe: Croatia
Croatian processing and manufacturing company with a long-history seeks financial support and land expansion.
Founded in 1916, the company has long been synonymous with high-quality tableware, kitchenware, woodworking machinery, tools and industrial knifes. The company has complete tableware production facilities, with an annual output of more than 10 million pieces, about 300 workers and an abundant plant area. It provides a full range of training services for workers, including component installation, equipment installation, start-up, industrial consulting and other services. It has long-term cooperation with famous companies such as Stihl, Villeroy & Boch, Rosenthal and Sheffield Metals in the UK, and exports different products to more than 20 countries around the world. The company hopes to expand its market, obtain franchise rights, or build its own sales center. The company is located in Central Europe and the Balkans, closely connected with ports, airports and highways, has a market of more than 500 million consumers, can fully vertically integrate all metal processing technologies, has EU financial support, has maintained a good relationship with scientific research institutes, and exports 70% of its products. The company has 37,000 square meters of land, 20,000 square meters of factories, more than 470 machines, sufficient space for technology development, and energy infrastructure: (4 MW electricity, pneumatic system (6 bar), tap water and cooling water). We are now seeking financial support for company expansion and plant expansion.
Europe: Croatia
Croatian toy manufacturing company with a long history seeks partners or acquisition.
The private company is created based on robot technology for toys, and STEM fields related teaching materials. The company has more than 25 years of experience in this field. Some hardware and software solutions developed by the company can be integrated with "fischertechnik" products.
Europe: Britain
British medical equipment company seeks for investment.
The company is developing a pump that can be implanted directly into the failing heart to treat advanced chronic heart failure. The company aims to apply novel technologies and designs to produce ventricular assist devices (VADs) with obvious advantages over existing methods, including less invasive surgery, reduced thrombosis and control systems optimized for quality of life. The company is raising £ 7.5 million and is now steadily realizing the first implantation of the company's products in the human body in 2021.
Europe: Britain
British clinical biotechnology company seeks for acquisition.
The company is a UK based clinical biotechnology company dedicated to the development of new anti-infectives. Founded in the UK in 1997, it was listed on the London Stock Exchange (LSE) sub market alternative investment market (AIM) in 2017, with a market value of £ 19 million. In 2018, the first new drug for research (IND) was successfully launched in the United States, has obtained fast track qualification, and is starting the planned clinical plan. The pilot drug code named XF-XX has completed a clinical trial funded by the U.S. government. Different from traditional antibiotics, XF-XX shows excellent resistance to a specified bacterial in the laboratory - producing a series of potential low bacterial resistance, which can be used to prevent and treat methicillin resistant Staphylococcus aureus (MRSA) infection. Compared with traditional antibiotics, XF platform has the advantages of killing bacteria quickly, killing bacteria in any growth period and killing bacteria in staphylococcal bacterial biofilm. It is active against all Gram-positive bacteria tested so far and selected Gram-negative bacteria. No bacterial (MRSA) resistance was found. The company continued to strengthen its patent rights and granted XF biofilm patents in Canada in 2018, bringing the total number of patents granted by XF platform to 95.
Europe: Finland
Finish medical R&D company seeks domestic investment or acquisition.
A private company, which is headquartered in Turku, Finland, dedicated to providing innovative diagnostic tools for routine clinical diagnosis and research. Based on its proprietary technology, the company has developed and commercialized the next generation of multifunctional micro detection tools. The advantages of this technology enable it to overcome the performance limitations of the previous generation test in terms of sensitivity, accuracy, ease of use and cost efficiency.
The testing equipment developed by the company has passed ISO 13485:2016 and ISO 9001:2015. This equipment is a cathode electrochemiluminescence instrument that can be used to measure the concentration of components in blood. The technology can be used for animal epidemic prevention. It is convenient and fast to use. The results can be obtained in 5-10 minutes with reliable accuracy. It can be viewed at any time on the independent display screen or mobile phone application on the equipment.
If the matching detection box is used together (the antibody has been wrapped on the chip without calibration), the analyzer can also be used to detect human C-reactive protein (CRP). Results can be displayed in 6-12 minutes from a full blood sample. It can be used to triage patients to reduce uncertainty and avoid unnecessary antibiotic use.
The testing equipment developed by the company has passed ISO 13485:2016 and ISO 9001:2015. This equipment is a cathode electrochemiluminescence instrument that can be used to measure the concentration of components in blood. The technology can be used for animal epidemic prevention. It is convenient and fast to use. The results can be obtained in 5-10 minutes with reliable accuracy. It can be viewed at any time on the independent display screen or mobile phone application on the equipment.
If the matching detection box is used together (the antibody has been wrapped on the chip without calibration), the analyzer can also be used to detect human C-reactive protein (CRP). Results can be displayed in 6-12 minutes from a full blood sample. It can be used to triage patients to reduce uncertainty and avoid unnecessary antibiotic use.
Europe: Britain
British biomedicine company seeks Chinese Partner.
The firm is a Contract Manufacture Organization (CMO) headquartered in the UK, manufacturing and sterile filling bottles for clinical trials and small volume commercial supply. The company was founded in 2011, has sales offices in Boston, the United States. The turnover in 2019 exceeded USD 10 million, and the EBITDA in 2019 exceeded about USD 1.4 million. Core business: sterile production, analysis and microbiological testing, clinical trial services, (CTS): labeling and packaging, release of qualified personnel (QP). The company specializes in production of liquid, lyophilized powder, cytotoxicity, chemical and biopharmaceutical products, including lyophilized powder or liquid, biological agents (peptides, proteins, antibodies, nucleic acids), small molecules and efficient cytotoxins. It has professional facilities: two dust-free rooms with freeze dryer and special cytotoxic and non cytotoxic clean rooms. Test capability: release test, including HPLC, SDS PAGE, ELISA, microbial detection - sterility and endotoxin, etc.
Europe: Italy
Italian sheet metal equipment manufacturer selling majority of the share.
The company was founded in 2001, produces sheet metal equipment, and has unique patented technology. In the more than ten years since entering the Chinese market, the company has completed many landmark construction projects and key projects, such as the CITIC Tower project.
At present, there are 7 domestic production lines that can produce products with specifications of "1200 * 2400 (mm)" and above.Aquisition can help to rapidly localize the products, to effectively reduce the price.
The main production facilities are located in the center of the Modena's ceramic zone in northern Italy. In fy2017, the company's revenue was € 83.2 million and EBITDA was € 13.2 million. The founding family is seeking to sell a majority stake (up to 70%). Over the last years income increased from 48.8 million Euros to 83.2 million Euros. EBITDA also increased from € 10.8 million in fy2015 to € 13.3 million in fy2017. Net debt increased from € 9.8 million to € 23.1 million in fy2017, mainly due to new shareholder loans of € 13 million. In 2017, 69% of the revenue was generated in overseas markets. European countries accounted for 31% of the revenue in fiscal 2017, with Spain, Poland, Germany, and France as the main markets. The Far East accounts for 13% of revenue, and the main markets are China, India, South Korea, and Japan. In fiscal 2017, North American sales increased by 36% to € 8.1 million.
At present, there are 7 domestic production lines that can produce products with specifications of "1200 * 2400 (mm)" and above.Aquisition can help to rapidly localize the products, to effectively reduce the price.
The main production facilities are located in the center of the Modena's ceramic zone in northern Italy. In fy2017, the company's revenue was € 83.2 million and EBITDA was € 13.2 million. The founding family is seeking to sell a majority stake (up to 70%). Over the last years income increased from 48.8 million Euros to 83.2 million Euros. EBITDA also increased from € 10.8 million in fy2015 to € 13.3 million in fy2017. Net debt increased from € 9.8 million to € 23.1 million in fy2017, mainly due to new shareholder loans of € 13 million. In 2017, 69% of the revenue was generated in overseas markets. European countries accounted for 31% of the revenue in fiscal 2017, with Spain, Poland, Germany, and France as the main markets. The Far East accounts for 13% of revenue, and the main markets are China, India, South Korea, and Japan. In fiscal 2017, North American sales increased by 36% to € 8.1 million.
Europe: Netherlands
Dutch radiofrequency technology company is seeking investment.
The team is an independent R&D group of a well-known semiconductor company in the Netherlands, in wireless communication, radio frequency technology and mixed signal processing. This project is suitable for listed or planned listed technology enterprises. The fast-forming European R&D center can effectively promote technology iteration and new product launch, and has independent core technology IP. The R&D team has Chinese technology leaders who have lived in Europe for many years as its core, and attracts high-level European R&D engineers. It can quickly form a R&D team of 6-10 people in 3-6 months, and the forming team can generally complete the design, development and testing of new products in 6-12 months. A mature 6-person R&D team probably has a budget of 4 million RMB/ year. The R&D center is recommended to settle in Eindhoven High-tech Park in the Netherlands.
Europe: Greece
Greece company seeks buyers for its paper mill
The paper mill covers an area of about 40,000 square meters and is located in Aspropirgos Attica region. EUR 1.49 million is needed to maintain daily operation. The bank offered EUR 3.2 million to auction the factory, with a total sale amount of EUR 4.69 million, and the average share price per square meter is EUR 117.25, which is lower than the average selling price of industrial land in the region.
Europe: Britain
British medical equipment company with production in Shenzhen looking for investors to grow their buisiness in China
The company has developed a portfolio of wearable light sources for medical and consumer health applications. There are two distinct product lines. Two products are clinically proven and easy to use for the treatment of specific skin diseases such as non-melanoma skin cancer and acne. The product is manufactured in Shenzhen, and the distribution partner has been appointed in China. It is expected to be provided online in China through T-Mall soon.
Europe: Britain
UK medical equipment manufacturer with clinically proven blood circulation stimulation device seeking investors for expansion to the United States
The company has developed patented neuromuscular electrical stimulation technology and a product that has been clinically proven to increase blood circulation. The product is the size of a watch and is worn behind the knee. It will send a small electric pulse to gently stimulate the common peroneal nerve behind the knee, and then activate the calf and foot muscle pump of the calf to return the blood to the heart. The technique has been developed for the treatment of deep venous thrombosis, advanced wound care, preoperative and postoperative edema reduction, incontinence and athlete rehabilitation. In each clinical field, it improves the prognosis of patients and saves sanitation system resources. The company is raising £ 30-35 million to continue clinical development, product development and marketing in the United States, valued at £ 114 million.
Europe: Britain
Cambridge based biotech R&D firm with unparalleled track record looking for investors
The company is a Cambridge based biotechnology contract research and drug development company, which operates a mixed business model. The revenue is generated through its service business and the development of drug products. The company has an excellent track record in candidate drug delivery. It has a world-class discovery team, and its unparalleled track record shows that it has delivered one candidate drug on behalf of its customers every year in the past six years. Revenue in 2019 was approximately £ 6 million, of which 83% of sales came from a strong growing industrial customer base, which has now become the core of the business.
Enquire for more information about our services, and how we can help solve challenges for your organization
Contact Us